Leuprolide High Sensitivity ELISA Kit (DEIA-XYZ93)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
serum, plasma
Species Reactivity
N/A
Intended Use
The Leuprolide EIA Kit is a competitive immunoassay for in vitro quantitative measurement of (Des-Gly10, D-Leu6, Pro-NHEt9)-LHRH (Leuprolide) in serum or plasma.
Contents of Kit
1. EIA buffer concentrate
2. 96-well immunoplate with acetate plate sealer
3. Anti serum (lyophilized powder)
4. Standard (1 ug lyophilized powder)
5. Biotinylated tracer (lyophilized powder)
6. Sreptavidin-HRP
7. TMB substrate solution
8. Stop solution
9. Standard diluent 8ml
10. Datasheet
11. Protocol
Storage
Lyophilized components and standard diluent at a constant -20°C, The remaining components should be stored in the refrigerator (2-4°C)
Performance Characteristics
AVERAGE IC50: 0.4 ng/ml
Detection Range
0-10 ng/ml
Standard Curve

Citations


Have you cited DEIA-XYZ93 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Pituitary Apoplexy After Initial Leuprolide Injection

WORLD NEUROSURGERY

Authors: Fabiano, Andrew J.; George, Saby

BACKGROUND: Pituitary apoplexy is a rare complication of the initial administration of leuprolide acetate. CASE DESCRIPTION: We present the case of a 63-year-old man who experienced headache, blurred vision, and loss of consciousness after initial leuprolide treatment for prostate carcinoma. Neuroimaging showed pituitary hemorrhage. CONCLUSIONS: Clinicians should be aware of this rare but known complication of leuprolide injection so that prompt diagnosis and treatment initiation are performed in patients with leuprolide-associated pituitary apoplexy.

Sex differences in visuospatial abilities persist during induced hypogonadism

NEUROPSYCHOLOGIA

Authors: Guerrieri, Gioia M.; Wakim, Paul G.; Keenan, P. A.; Schenkel, Linda A.; Berlin, Kate; Gibson, Carolyn J.; Rubinow, David R.; Schmidt, Peter J.

Background: Despite well-established sex differences in the performance on tests of several cognitive domains (e.g., visuospatial ability), few studies in humans have evaluated if these sex differences are evident both in the presence of circulating sex hormones and during sex steroid hormonal suppression. Sex differences identified in the relative absence of circulating levels of estradiol and testosterone suggest that differences in brain structure or function exist independent of current hormonal environment and are more likely a reflection of differing developmental exposures and/or genetic substrates. Objective: To evaluate cognitive performance in healthy eugonadal men and women before and again during GnRH agonist-induced hypogonadism. Methods: Men (n=16) and women (n=15) without medical or psychiatric illness were matched for IQ. Cognitive tests were performed at baseline (when eugonadal) and after 6-8 weeks of GnRH agonistinduced gonadal suppression. The test batteries included measures of verbal and spatial memory, spatial ability, verbal fluency, motor speed/dexterity, and attention/concentration. Data were analyzed using repeated-measures models. Results: During both eugonadism and hypogonadism, men performed significantly better than women on several measures of visuospatial performance including mental rotation, line orientation, Money Road Map, Porteus maze, and complex figure drawing. Although some test performances showed an effect of hormone treatment, the majority of these differences reflected an improved performance during hypogonadism compared with baseline (and probably reflected practice effects). Conclusion: The well-documented male advantage in visuospatial performance, which we observed during eugonadal conditions, was maintained in the context of short-term suppression of gonadal function in both men and women. These findings suggest that, in humans, sex differences in visuospatial performance are not merely dependent on differences in the current circulating sex steroid environment. Thus sex differences in visuospatial performance in adulthood could reflect early developmental effects of sex steroid exposure or other environmental exposures differing across the sexes as our data confirm that these differences are independent of circulating estradiol or testosterone levels in men and women. Published by Elsevier Ltd.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket